# SSKN earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/SSKN) · [Earnings tab](https://www.lopjlb.com/stock/SSKN?tab=earnings) Updated: 2026-08-19T06:25:21 Quarters analyzed: 8 ## Cross-quarter narrative Across 8 calls for SSKN, management tone moved from +0.00 (2023 Q4) to +0.50 (2025 Q3). Latest guidance stance: maintained. Latest desk line: Revenue fell 20% YoY driven by international trade headwinds, but recurring revenue held steady, CPT code expansion and Elevate360 program fuel optimism for a stronger Q4 and future growth. ## Latest CallCard · Q3 Revenue fell 20% YoY driven by international trade headwinds, but recurring revenue held steady, CPT code expansion and Elevate360 program fuel optimism for a stronger Q4 and future growth. **Guidance:** maintained — Management expects a seasonally stronger Q4 and continued growth from expanded CPT codes and Elevate360 initiatives. **Tone:** mgmt 0.5 · Q&A pressure 0.6 · divergence 0.4 We are extremely passionate and excited about a seasonally stronger fourth quarter, tripling patient population with expanded indications and favorable reimbursement trends. ### Demand visibility Demand expected to grow with expanded CPT codes but visibility limited by trade policy and CMS timing. The expansion to over 30 indications and private payer outreach should triple addressable market, yet US tariff policy and the 2027 code effective date keep short‑term demand visibility uncertain. ### Margins / costs Gross margin remained flat despite revenue decline. Gross profit was $4.2M (60% of revenue) and gross margin was roughly flat YoY; equipment revenue fell 60% while recurring revenue grew, keeping overall margin stable. ### Capital allocation Capital deployed to offering, Elevate360, litigation and international expansion. Raised $2.2M net in a direct offering; invested in Elevate360 clinic support, litigation enforcement, and Mexico TheraClear registration and commercial rollout. ### Milestones - **CPT code expansion** [new]: CMS recognized expanded codes in 2026 fee schedule; effective Jan 1 2027, expanding reimbursement to >30 indications. - **Elevate360 program** [on_track]: 99 of 838 clinics entered Elevate360, delivering ~7% YoY growth for those accounts. - **Mexico TheraClear launch** [on_track]: TheraClear registered with Cofepris and first commercial placement announced; aim for multiple placements by year‑end. - **LaserOptik litigation** [on_track]: Injunction secured; pursuing damages and recovery of ~2 dozen devices, with 75‑100 accounts targeted for return. - **Direct offering** [delivered]: Raised $2.2M net capital in a straight common registered direct offering. ### Fears / risks - **Regulatory/Reimbursement**: Expanded CPT codes only effective 2027; uncertainty around temporary codes could delay revenue uplift. - **International Trade**: U.S. tariff policy creates uncertainty and pressure on international sales, especially in China. - **Litigation**: Outcome of LaserOptik lawsuit and potential damages are uncertain, though injunction is favorable. - **Device Recovery**: Recovery of lost accounts (75‑100) depends on litigation and clinic decisions, affecting future revenue. - **Revenue Decline**: Overall revenue down 20% YoY, driven by equipment sales slump and international weakness. - **Capital Constraints**: Reliance on a $2.2M offering may limit ability to fund larger expansion initiatives. - **Market Adoption**: Success of Elevate360 and DTC campaigns hinges on clinic uptake and patient conversion rates. - **Temporary CPT Code Uncertainty**: CMS indicated no temporary codes for 2026, potentially postponing early reimbursement benefits. ### Key quotes > “Key to the progress will be the historic expansion of CPT codes for STRATA's XTRAC 308-nanometer excimer laser, which are expected to become effective January 1, 2027.” > “CMS thought it would not be a good or wise thing to create temporary codes for the 2026 cycle.” ## Quarter one-liners - **2025 Q3:** Revenue fell 20% YoY driven by international trade headwinds, but recurring revenue held steady, CPT code expansion and Elevate360 program fuel optimism for a stronger Q4 and future growth. - **2025 Q2:** SSKN Q2 2025: Revenue fell 9% to $7.7M; expanded CPT codes for XTRAC could triple TAM by 2027; LaserOptek litigation ongoing with potential 8-digit damages; Elevate 360 consulting showing early success. - **2025 Q1:** STRATA Skin Sciences Q1 2025: Turnaround strategy driving recurring revenue per device growth, Elevate 360 consulting expanding, TheraClearX deployments rising, but tariffs threaten international revenue. - **2024 Q4:** STRATA Skin Sciences reported a strong Q4 2024 with revenue up 10%, gross margin improving to 60%, higher device utilization and expanding international sales, but offered only vague guidance and noted tariff and currency risks. - **2024 Q3:** STRATA Skin Sciences posted Q3 2024 revenue flat, improved gross margin to 60.3%, first operating profit since 2018 (ex‑tax), grew DTC appointments to 1,900 YTD, added TheraClearX devices, raised $2.1M equity and secured a partial litigation win. - **2024 Q2:** STRATA Skin posted modest revenue growth, cut operating costs, expanded DTC marketing and equipment sales, while working to improve margins and optimize its device base. - **2024 Q1:** STRATA Skin Sciences reports Q1 2024 revenue decline but narrowing recurring billings, cost cuts, and expanding DTC marketing as it optimizes device placement. - **2023 Q4:** — ## Theme arcs - **Management tone** (improving): Δ mgmt=+0.50 ## Fear persistence - **device utilization risk** [resolved]: 2024 Q1 - **marketing execution risk** [resolved]: 2024 Q1 - **depreciation cost risk** [resolved]: 2024 Q1 - **geographic concentration risk** [resolved]: 2024 Q1 - **liquidity risk** [resolved]: 2024 Q1 - **revenue recognition risk** [resolved]: 2024 Q1 - **product adoption risk** [resolved]: 2024 Q1 - **execution timeline risk** [resolved]: 2024 Q1 - **margin pressure** [resolved]: 2024 Q2 - **installed base shrinkage** [resolved]: 2024 Q2 ## Guidance path 2023 Q4:vague → 2024 Q1:vague → 2024 Q2:maintained → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/SSKN`